Who makes Mitefosine?

Mitefosine is developed by International Centre for Diarrhoeal Disease Research, Bangladesh.

What development phase is Mitefosine in?

Mitefosine is FDA-approved (marketed).

Last reviewed 2026-04-19 · How we verify

Mitefosine

International Centre for Diarrhoeal Disease Research, Bangladesh · FDA-approved active Small molecule

At a glance

Generic name	Mitefosine
Also known as	Brand name: Impavido
Sponsor	International Centre for Diarrhoeal Disease Research, Bangladesh
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Mitefosine CI brief — competitive landscape report
Mitefosine updates RSS · CI watch RSS
International Centre for Diarrhoeal Disease Research, Bangladesh portfolio CI